Trial Profile
Comparison of Neurotoxic Potential of Abraxane versus Oxaliplatin and Paclitaxel chemotherapy in cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Oxaliplatin
- Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 25 Mar 2022 Status changed from recruiting to completed.
- 11 Aug 2016 Status changed from not yet recruiting to recruiting.
- 30 Jun 2016 New trial record